Compare Medpace Holdings Inc (MEDP) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Transocean Ltd — how do they compare? Medpace Holdings Inc trades at $610.04 (market cap $16.82B), while Transocean Ltd trades at $5.55 (market cap $6.19B). The key difference: Medpace Holdings Inc is far larger — about 2.7× Transocean Ltd's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Transocean Ltd for 18 Days on average.
| MEDP | RIG | |
|---|---|---|
Market Cap | $16.82B | $6.19B |
Volume | 223,093 | 30,564,415 |
Sector | Health | Energy |
52-Week High | $630.19 | $7.58 |
52-Week Low | $393.42 | $3.08 |
Typical Hold Time | 14 Days | 18 Days |
Enterprise Value | $16.44B | $10.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Transocean (RIG) trades at $5.595, up 3.8% with bullish technical signals despite mixed earnings. The company shows strong revenue growth to $4.1B in 2026 but remains unprofitable with a -40.24% net margin. Recent $80M and $300M contract wins boost backlog, while the $5.8B Valaris acquisition advances after DOJ approval. Cash flow improved with $995M operating cash in 2026, supporting deleveraging efforts amid high debt levels.
RIG offers speculative upside through offshore cycle leverage and contract growth, but high debt and persistent losses pose significant risks. Analyst consensus is divided with 39% buy ratings, reflecting optimism about cash flow improvement versus concerns over profitability and execution risks from major acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
